Clinical significance of TLR3 and TLR4 in peripheral blood mononuclear cells from children with Henoch-Schönlein purpura nephritis

The aim of the present study was to investigate the expression levels and clinical significance of Toll-like receptor (TLR) 3 and 4 in peripheral blood mononuclear cells (PBMCs) collected from children with Henoch-Schönlein purpura (HSP) nephritis. The randomized controlled trial was conducted between August 2011 and March 2013, and 105 children with a clinical diagnosis of HSP were enrolled in the study. According to the 24-h urinary protein measurements and the presence of renal damage, the 105 cases were divided into groups A, B and C as follows: Group A, children with HSP but without renal damage; group B, children with HSP nephritis but without proteinuria; group C, children with HSP nephritis and proteinuria. A total of 30 healthy children were enrolled in the normal control group (group N). The primary endpoints were the detection of TLR3 and 4 mRNA and protein expression levels in PBMCs by flow cytometry and quantitative polymerase chain reaction. The mRNA and protein expression levels of TLR4 in the PBMCs were significantly higher in groups A, B and C when compared with group N. In addition, the mRNA and protein expression levels of TLR4 in group C were much higher when compared with groups A and B. A positive correlation was identified between TLR4 protein expression and 24-h urinary protein levels in group C. The expression levels of TLR3 did not significantly differ among the groups. Protein and mRNA expression levels of TLR4 in PBMCs significantly increased and exhibited a positive correlation with urinary protein excretion. These results indicate that aberrant activation of TLR4 may be relevant to the development of HSP nephritis.

[1]  C. Daniel,et al.  Toll-like receptor 2 is required for autoantibody production and development of renal disease in pristane-induced lupus. , 2013, Arthritis and rheumatism.

[2]  C. Qian,et al.  Regulation of Toll‐like receptor signaling pathways in innate immune responses , 2013, Annals of the New York Academy of Sciences.

[3]  M. Kirchner,et al.  Surface expression and genotypes of Toll-like receptors 2 and 4 in patients with juvenile idiopathic arthritis and systemic lupus erythematosus , 2013, Pediatric Rheumatology.

[4]  A. Baxter,et al.  Role of toll-like receptors in multiple sclerosis. , 2013, American journal of clinical and experimental immunology.

[5]  Michael Maes,et al.  Role of the Toll Like Receptor (TLR) Radical Cycle in Chronic Inflammation: Possible Treatments Targeting the TLR4 Pathway , 2013, Molecular Neurobiology.

[6]  T. Eleftheriadis,et al.  Toll-like receptors and their role in renal pathologies. , 2012, Inflammation & allergy drug targets.

[7]  J. Thurman,et al.  Complement activation and toll-like receptor-2 signaling contribute to cytokine production after renal ischemia/reperfusion. , 2012, Molecular immunology.

[8]  G. Gumuser,et al.  Assessment of Toll‐like receptor‐4 gene polymorphism on pyelonephritis and renal scar , 2012, International journal of immunogenetics.

[9]  A. E. Yeo,et al.  The Effects of TLR Activation on T-Cell Development and Differentiation , 2012, Clinical & developmental immunology.

[10]  A. Aderem,et al.  Cross-interference of RLR and TLR signaling pathways modulates antibacterial T cell responses , 2012, Nature Immunology.

[11]  R. Golub,et al.  JAMA patient page. Henoch-Schönlein purpura. , 2012, JAMA.

[12]  K. Mills,et al.  TLR-dependent T cell activation in autoimmunity , 2011, Nature Reviews Immunology.

[13]  Hong Wang,et al.  TLR-signaling Networks , 2011, Journal of dental research.

[14]  T. Jahnukainen,et al.  Clinical course of extrarenal symptoms in Henoch–Schönlein purpura: a 6-month prospective study , 2010, Archives of Disease in Childhood.

[15]  M. Banach,et al.  The role of Toll-like receptors in renal diseases , 2010, Nature Reviews Nephrology.

[16]  R. Camilla,et al.  Toll‐like receptor 4 expression is increased in circulating mononuclear cells of patients with immunoglobulin A nephropathy , 2010, Clinical and experimental immunology.

[17]  J. Novak,et al.  Pathogenesis of Henoch-Schönlein purpura nephritis , 2009, Pediatric nephrology (Berlin, West).

[18]  H. Anders,et al.  Bacterial lipopeptide triggers massive albuminuria in murine lupus nephritis by activating Toll‐like receptor 2 at the glomerular filtration barrier , 2009, Immunology.

[19]  S. Sacks,et al.  Toll-like receptor 2 agonists exacerbate accelerated nephrotoxic nephritis. , 2006, Journal of the American Society of Nephrology : JASN.

[20]  P Woo,et al.  EULAR/PReS endorsed consensus criteria* for the classification of childhood vasculitides , 2005, Annals of the rheumatic diseases.

[21]  S. Mrusek,et al.  Henoch-Schönlein purpura , 2004, The Lancet.

[22]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.